Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dual inhibition of VEGF and PARP suppresses KRAS-mutant colorectal cancer.

Neoplasia (New York, N.Y.) - 1 Sept 2020

Zhong Longhui, Wang Rong, Wang Yanxia, Peng Shunli, Ma Yueyun, Ding Sijie, Yang Hong, Chen Shiyu, Luo Xiaoqing, Wang Wei

Abstract excerpt

The addition of bevacizumab to chemotherapy has prolonged overall and progression-free survival rates for metastatic colorectal cancer (mCRC). However, KRAS-mutant (KRAS-mut) CRC, lacking an ideal targeted agent, represents an inferior-response subgroup of patients. In the present study, we investigated a combination approach of bevacizumab + olaparib in KRAS-mut CRC in a preclinical setting. The combined therapy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Bevacizumab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Nude

Share to Phthalazines

Share to Piperazines

Share to Poly (ADP-Ribose) Polymerase-1

Share to Vascular Endothelial Growth Factor A

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 32629177
DOI: 10.1016/j.neo.2020.06.001
PMCID: PMC7339053

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dual inhibition of VEGF and PARP suppresses KRAS-mutant colorectal cancer.PMID 32629177Read ↗

Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanismsSemantic proximity Read ↗

Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial.Semantic proximity Read ↗

Vitamin C activates pyruvate dehydrogenase (PDH) targeting the mitochondrial tricarboxylic acid (TCA) cycle in hypoxic KRAS mutant colon cancer.Semantic proximity Read ↗

Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.Semantic proximity Read ↗

Oncogenic KRAS modulates mitochondrial metabolism in human colon cancer cells by inducing HIF-1α and HIF-2α target genesSemantic proximity Read ↗

A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin.Semantic proximity Read ↗

Low-dose metronomic cyclophosphamide treatment mediates ischemia-dependent K-ras mutation in colorectal carcinoma xenografts.Semantic proximity Read ↗

Mir-675-5p supports hypoxia-induced drug resistance in colorectal cancer cellsSemantic proximity Read ↗

MITF regulates the subcellular location of HIF1α through SUMOylation to promote the invasion and metastasis of daughter cells derived from polyploid giant cancer cellsSemantic proximity Read ↗

Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines.Semantic proximity Read ↗

Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer.Semantic proximity Read ↗

CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.